MedTrace Logo

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT02207504 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-01-06

No results posted yet for this study

Summary

This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Castration-resistant Prostate Cancer

Interventions

DRUG

Crizotinib

Crizotinib is an ATP-competitive small-molecule inhibitor of the ALK, c-Met/HGFR, RON, and ROS receptor tyrosine kinases.

DRUG

Enzalutamide

Enzalutamide is an androgen receptor signaling inhibitor.

Sponsors & Collaborators

Principal Investigators

  • Christopher Sweeney, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2018-02-02
Completion
2022-01-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02207504 on ClinicalTrials.gov